OSI Chronicles

OSI Chronicles

Shares of OSI Pharmaceuticals Inc. jumped 139% to an all-time high of $91.10 in April 2004 when Tarceva erlotinib met the primary endpoint in a Phase III trial in non-small cell lung cancer (NSCLC). Since then, the stock has traded between $25-$50, as the company faced a number of disappointments including failures associated with its acquisitions of Cell Pathways Inc. and Eyetech Pharmaceuticals Inc.Aptosyn exisulind